glp-1 receptor agonist side effects Agonists of the metabolic effect and

Glucagon-like Peptide-1 receptor Tie2 + cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction

These mechanisms occur within hours after GCs administration and may lead to hyperglycemia, even in individuals without a prior history of glucose abnormalities ( Figure 1 The clinical impact of hyperglycemia during GCs therapy has been well established, with multiple studies reporting increased morbidity and mortality, including higher rates of infection, cardiovascular events and prolonged hospitalisations ( Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are not currently recommended in SID by major guidelines, their mechanism of action makes them promising candidates to counteract the metabolic impacts of steroids

Lilly has submitted orforglipron for approval in more than 40 countries, with launches expected in each market following regulatory clearance

Pediatric patients aged 12 to 17 must have a weight in the 95th percentile for their age and sex

How common is gastroparesis

Preliminary results from the SURPASS-J-mono study in Japanese patients with T2D who were either therapy nave or on an antidiabetic monotherapy showed a head-to-head comparison of a tirzepatide treatment compared to therapy with the GLP-1RA dulaglutide at a dose of 0.75 mg (54, 76)